Results 41 to 50 of about 15,669 (253)

Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts: the silence study [PDF]

, 2018
Background. We investigated low-dose aspirin (ASA) efficacy and safety in subjects with silent brain infarcts (SBIs) in preventing new cerebrovascular (CVD) events as well as cognitive impairment. Methods.
Altieri, Marta, Bastianello, Stefano, Carlucci, Giovanna, Cavallini, Anna, Coppola, Cristiana, Di Clemente, Laura, Di Giuseppe, Matteo, Di Piero, Vittorio, Federico, Francesco, Inzitari, Domenico, Lucivero, Vincenzo, Maestrini, Ilaria, Marini, Carmine, Mezzapesa, Domenico Maria, Micieli, Giuseppe, Pantano, Patrizia, Paolino, Isabella, Parnetti, Lucilla, Peducci, Maria, Persico, Alessandra, Prontera, Maria Pia, Provinciali, Leandro, Raz, Eytan, Russo, Tommasina, Sarchielli, Paola, Serrati, Carlo, Silvestrini, Mauro, Vicenzini, Edoardo, Zat, Carla   +28 more
core   +1 more source

The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice. [PDF]

PLoS ONE, 2012
It is important to identify effective contraceptive drugs that cause minimal disruption to physiological processes. Phosphodiesterase 3 (PDE3) inhibitors suppress meiosis in oocytes by decreasing the level of cAMP and blocking the extrusion of the first ...
Min Li, Yang Yu, Jie Yan, Li-Ying Yan, Yue Zhao, Rong Li, Ping Liu, Aaron J Hsueh, Jie Qiao   +8 more
doaj   +1 more source

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B., Demchuk, A., Kasner, S.E., Lees, K.R., Levine, S.R., Lyden, P., Messe, S.R., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model

Scientific Reports
Cilostazol has previously been shown to reduce liver steatosis and enhance hepatic perfusion. We investigated the effects of cilostazol after major hepatectomy in a steatotic rat model. Six weeks prior to surgery, Sprague–Dawley rats were fed with a high-
Sebastian Holländer, Maximilian von Heesen, Gereon Gäbelein, Julie Mercier, Matthias W. Laschke, Michael D. Menger, Matthias Glanemann, Antonios E. Spiliotis   +7 more
doaj   +1 more source

A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis [PDF]

, 2003
Background Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis.
Choi, D, Ho, DSW, Hong, MK, Jang, Y, Lam, R, Lee, CW, Mintz, GS, Park, SJ, Park, SW, Raizner, AE, Shim, WH, Weissman, NJ   +11 more
core   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis. [PDF]

PLoS ONE, 2015
Cilostazol has been reported to alleviate the metabolic syndrome induced by increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, which is also associated with osteoclast (OC) differentiation. We hypothesized that bone loss might be
Ke Ke, Ali Muhammad Safder, Ok-Joo Sul, Jae-Hee Suh, Yeonsoo Joe, Hun-Taeg Chung, Hye-Seon Choi   +6 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Rehabilitation and return to activity after platelet‐rich plasma injections in chronic tendinopathies: Consensus from international experts

PM&R, EarlyView.
Abstract Background The effectiveness of platelet‐rich plasma (PRP) injections in chronic tendinopathies remains debated. Although the product's characteristics play a role, the impact of postinjection recommendations remains poorly investigated. Objective To establish principles and guidelines for post‐PRP injection rehabilitation and return to ...
Vincent Gremeaux, Martin Lamontagne, Valérie Bélanger, Etienne Dalmais, Eric Noël, Alain Frey, Paul Ornetti, Fadoua Allali, Jimmy Gross, F. Michel, Hervé Bard, Jean‐François Kaux, the GRIIP (Groupe de Recherche International sur les Injections de Plaquettes; International Research Group on Platelet Injections)   +12 more
wiley   +1 more source